시장보고서
상품코드
1429586

세계의 췌장암 치료제 시장 보고서(2024년)

Pancreatic Cancer Drugs Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

췌장암 치료제 시장 규모는 향후 몇 년동안 꾸준히 성장할 것으로 예상됩니다. 2028년에는 4.0%의 연평균 복합 성장률(CAGR)로 46억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 암 발병률 증가, 의료비 급증, 정부 지원 확대에 기인하는 것으로 보입니다. 이 기간 동안 예상되는 주목할 만한 동향으로는 췌장암 치료용 신약 개발 집중, 새로운 나노 의료 치료에 대한 집중, 투자 증가, 제휴에 대한 전략적 초점, 제품 혁신에 대한 노력 등이 있습니다.

췌장암 치료제 시장의 예상 성장은 췌장암 유병률 증가로 인해 촉진될 것으로 예상됩니다. 췌장암 환자 수가 증가함에 따라 의약품에 대한 수요가 증가하여 시장 성장을 가속할 것으로 예상됩니다. 암의 급증은 주로 고령화 및 비만 인구 증가와 같은 요인에 기인합니다. 예를 들어, 미국암협회는 2023년 약 6만 4,050명(남성 3만 3,130명, 여성 3만 920명)이 췌장암 진단을 받고 약 5만 550명(남성 2만 6,620명, 여성 2만 3,930명)이 췌장암으로 사망할 것으로 추산하고 있습니다.

췌장암에 초점을 맞춘 정부의 이니셔티브와 자금 지원은 췌장암 치료제 시장의 성장을 가속할 준비가 되어 있습니다. 이러한 정부 지원에는 공공 서비스 및 경제 전반에 기여하는 프로젝트와 아이디어를 가진 선별된 단체에 재정적 지원을 제공하는 것이 포함됩니다. 이러한 지원은 췌장암 환자의 삶의 질과 생존율 향상을 목표로 하는 췌장암 연구에 특히 중요합니다. 일례로 2021년 7월 미국 국립암연구소는 췌장암 연구에 2억 달러를 배정했습니다. 따라서 정부의 이니셔티브와 자금 지원으로 인한 추진력은 췌장암 치료제 시장 성장의 중요한 원동력이 될 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

  • 세계의 췌장암 치료제 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 췌장암 치료제 시장 규모 실적과 성장, 2018-2023년
  • 세계의 췌장암 치료제 시장 규모와 성장 예측, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 췌장암 치료제 시장, 유형별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 내분비 췌장암
  • 외분비 췌장암
  • 세계의 췌장암 치료제 시장, 약제별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • Afinitor
  • Erlotinib
  • Hydrochloride Everolimus
  • 5-FU
  • Flurouracil
  • Gemcitanine
  • Abraxane
  • 세계의 췌장암 치료제 시장, 최종사용자별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원
  • 클리닉
  • 기타

제7장 지역 및 국가별 분석

  • 세계의 췌장암 치료제 시장, 지역별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 췌장암 치료제 시장, 국가별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 췌장암 치료제 시장 경쟁 구도
  • 췌장암 치료제 시장 기업 개요
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • AstraZeneca PLC
    • F. Hoffmann-La Roche AG
    • Novartis AG

제31장 기타 주요 기업과 혁신 기업

  • AbbVie Inc.
  • Merck &Co., Inc.
  • Teva Pharmaceutical Industries
  • Amgen Incorporation
  • Eli Lilly And Company
  • Beigene
  • Chi-Med
  • Cstone Pharmaceuticals
  • Voxtur Bio Ltd
  • Shantu Pharma
  • Krushi Mitra
  • Kremedine Health Private Limited
  • Arlak Biotech
  • Healthkind Labs Pvt. Ltd
  • Swisschem Healthcare Pvt Ltd

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 잠재성 분석

제36장 부록

LSH 24.03.08

Pancreatic cancer drugs refer to medications designed for treating pancreatic cancer, a condition resulting from uncontrolled cell growth in the pancreas. This abnormal growth disrupts the pancreas' production of digestive juices and hormones responsible for regulating blood sugar levels. Tissue lumps, known as tumors, develop due to this excessive cell growth, impeding the normal functioning of the pancreas.

Pancreatic cancer drugs can be categorized into two main types endocrine pancreatic cancer and exocrine pancreatic cancer. Exocrine pancreatic cells generate enzymes released into the small intestine to aid in the digestion of food as it traverses the digestive tract. The diverse range of drugs for pancreatic cancer treatment includes Afinitor, erlotinib, hydrochloride everolimus, 5-FU (fluorouracil), gemcitabine, and Abraxane. These drugs find application in various healthcare settings, including hospitals, clinics, and others.

The pancreatic cancer drugs market research report is one of a series of new reports from The Business Research Company that provides pancreatic cancer drugs market statistics, including pancreatic cancer drugs industry global market size, regional shares, competitors with a pancreatic cancer drugs market share, detailed pancreatic cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer drugs industry. This pancreatic cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic cancer drugs market size has grown steadily in recent years. It will grow from $3.83 billion in 2023 to $3.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The historical period's growth can be attributed to robust economic expansion in emerging markets, a growing aging population, and an increased incidence of pancreatic cancer.

The pancreatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $4.65 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The anticipated growth in the forecast period can be ascribed to an increase in cancer incidence rates, a surge in healthcare expenditure, and growing government support. Notable trends expected during this period include a concentration on the development of new drugs for pancreatic cancer treatment, an emphasis on novel nanomedicine treatment, an increase in investments, a strategic focus on collaborations, and a dedication to product innovations.

The anticipated growth of the pancreatic cancer drugs market is driven by the increasing prevalence of pancreatic cancer. The elevated number of pancreatic cancer cases is expected to boost the demand for drugs, consequently fueling market growth. The surge in cancer instances is largely attributed to factors such as an aging population and a growing number of people dealing with obesity. For example, the American Cancer Society estimates that in 2023, approximately 64,050 individuals (33,130 men and 30,920 women) will receive a pancreatic cancer diagnosis, and about 50,550 people (26,620 men and 23,930 women) will succumb to pancreatic cancer.

Government initiatives and funding focused on pancreatic cancer are poised to drive further growth in the pancreatic cancer drugs market. Such governmental support involves providing financial assistance to selected entities with projects or ideas contributing to the enhancement of public services and the overall economy. This support is particularly crucial for pancreatic cancer research aimed at improving the quality of life and survival rates for patients with this condition. As an illustration, in July 2021, the National Cancer Institute, a US-based government agency, allocated 218.1 million US Dollars for pancreatic cancer research. Therefore, the impetus provided by government initiatives and funding is a significant driver of growth in the pancreatic cancer drugs market.

An ongoing trend in the pancreatic cancer drugs market is the preference for combination therapy over monotherapy. Recognizing the potential to enhance drug efficacy and improve the survival rates of patients with pancreatic cancer, major players in the market are increasingly exploring the combination of two or more drugs. Companies such as Rafael Pharmaceuticals have initiated pivotal Phase 3 trials, such as AVENGER 500, combining CPI-613 (delimitate) with Modified FOLFIRINOX as a first-line treatment for patients with Metastatic Pancreatic Cancer. Apexigen, Inc., a clinical-stage biopharmaceutical company, is also investing in combination therapy, presenting new clinical data on APX005M for patients with metastatic pancreatic cancer.

To gain a competitive edge, major companies in the pancreatic cancer drugs market are investing in local drug delivery systems. This approach involves administering drugs directly to the site of action, enhancing efficacy while minimizing side effects. For instance, OncoLize, a Netherlands-based company, raised a US$ 1.7 million seed investment round in April 2023 to extend their preclinical success with a local drug delivery system for treating pancreatic and lung cancer. This innovative product utilizes unique liquid formulations to deliver a variety of anti-cancer drugs more effectively, both traditional chemotherapy drugs and modern immuno-drugs.

In April 2021, Servier, a France-based pharmaceutical company, acquired Agios Pharmaceuticals for an undisclosed amount. This strategic acquisition strengthens Servier's oncology portfolio, as Agios Pharmaceuticals is a US-based company specializing in drug development, including pancreatic cancer drugs.

Major companies operating in the pancreatic cancer drugs market report are Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Novartis AG, Abbvie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries, Amgen Incorporation, Eli Lilly And Company, Beigene, Chi-Med, Cstone Pharmaceuticals, Voxtur Bio Ltd., Shantu Pharma, Krushi Mitra, Kremedine Health Private Limited, Arlak Biotech, Healthkind Labs Pvt. Ltd., Swisschem Healthcare Pvt Ltd., Apikos Pharma, Kolaz Biotech, Aqvida Gmbh, Baxter International Inc (Uk), Glaxosmithkline PLC, Veropharm, Biocad, Celon Pharma, Celgene Corporation, Johnson & Johnson, Bayer Ag, Eurofarma Laboratorios S.A, Tuteur Argentina, Neopharma Llc, Tabuk Pharmaceuticals, Julphar Life Sciences, Eurolab, Sanofi, Aspen, Zahraa Oncology, Adcock Ingram

North America was the largest region in the pancreatic cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global pancreatic cancer drugs market share during the forecast period. The regions covered in the pancreatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pancreatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The pancreatic cancer drugs market consists of sales of Gemcitabine (Gemzar), 5-fluorouracil (5-FU), and Irinotecan (Camptosar). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Pancreatic Neuroendocrine Cancer Drugs; Pancreatic Exocrine Cancer Drugs
  • 2) By Drug Combination: Single; Double; Triplet; Quadruplet
  • 3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
  • Companies Mentioned: Bristol-Myers Squibb Company; Pfizer Inc.; AstraZeneca PLC; F. Hoffmann-La Roche AG; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pancreatic Cancer Drugs Market Characteristics

3. Pancreatic Cancer Drugs Market Trends And Strategies

4. Pancreatic Cancer Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Pancreatic Cancer Drugs Market Size and Growth

  • 5.1. Global Pancreatic Cancer Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pancreatic Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pancreatic Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pancreatic Cancer Drugs Market Segmentation

  • 6.1. Global Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Endocrine Pancreatic Cancer
  • Exocrine Pancreatic Cancer
  • 6.2. Global Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Afinitor
  • Erlotinib
  • Hydrochloride Everolimus
  • 5-FU
  • Flurouracil
  • Gemcitanine
  • Abraxane
  • 6.3. Global Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Other End-Users

7. Pancreatic Cancer Drugs Market Regional And Country Analysis

  • 7.1. Global Pancreatic Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pancreatic Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pancreatic Cancer Drugs Market

  • 8.1. Asia-Pacific Pancreatic Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pancreatic Cancer Drugs Market

  • 9.1. China Pancreatic Cancer Drugs Market Overview
  • 9.2. China Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pancreatic Cancer Drugs Market

  • 10.1. India Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pancreatic Cancer Drugs Market

  • 11.1. Japan Pancreatic Cancer Drugs Market Overview
  • 11.2. Japan Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pancreatic Cancer Drugs Market

  • 12.1. Australia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pancreatic Cancer Drugs Market

  • 13.1. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pancreatic Cancer Drugs Market

  • 14.1. South Korea Pancreatic Cancer Drugs Market Overview
  • 14.2. South Korea Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pancreatic Cancer Drugs Market

  • 15.1. Western Europe Pancreatic Cancer Drugs Market Overview
  • 15.2. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pancreatic Cancer Drugs Market

  • 16.1. UK Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pancreatic Cancer Drugs Market

  • 17.1. Germany Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pancreatic Cancer Drugs Market

  • 18.1. France Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pancreatic Cancer Drugs Market

  • 19.1. Italy Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pancreatic Cancer Drugs Market

  • 20.1. Spain Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pancreatic Cancer Drugs Market

  • 21.1. Eastern Europe Pancreatic Cancer Drugs Market Overview
  • 21.2. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pancreatic Cancer Drugs Market

  • 22.1. Russia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pancreatic Cancer Drugs Market

  • 23.1. North America Pancreatic Cancer Drugs Market Overview
  • 23.2. North America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pancreatic Cancer Drugs Market

  • 24.1. USA Pancreatic Cancer Drugs Market Overview
  • 24.2. USA Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pancreatic Cancer Drugs Market

  • 25.1. Canada Pancreatic Cancer Drugs Market Overview
  • 25.2. Canada Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pancreatic Cancer Drugs Market

  • 26.1. South America Pancreatic Cancer Drugs Market Overview
  • 26.2. South America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pancreatic Cancer Drugs Market

  • 27.1. Brazil Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pancreatic Cancer Drugs Market

  • 28.1. Middle East Pancreatic Cancer Drugs Market Overview
  • 28.2. Middle East Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pancreatic Cancer Drugs Market

  • 29.1. Africa Pancreatic Cancer Drugs Market Overview
  • 29.2. Africa Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pancreatic Cancer Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Pancreatic Cancer Drugs Market Competitive Landscape
  • 30.2. Pancreatic Cancer Drugs Market Company Profiles
    • 30.2.1. Bristol-Myers Squibb Company
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AstraZeneca PLC
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. F. Hoffmann-La Roche AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Pancreatic Cancer Drugs Market Other Major And Innovative Companies

  • 31.1. AbbVie Inc.
  • 31.2. Merck & Co., Inc.
  • 31.3. Teva Pharmaceutical Industries
  • 31.4. Amgen Incorporation
  • 31.5. Eli Lilly And Company
  • 31.6. Beigene
  • 31.7. Chi-Med
  • 31.8. Cstone Pharmaceuticals
  • 31.9. Voxtur Bio Ltd
  • 31.10. Shantu Pharma
  • 31.11. Krushi Mitra
  • 31.12. Kremedine Health Private Limited
  • 31.13. Arlak Biotech
  • 31.14. Healthkind Labs Pvt. Ltd
  • 31.15. Swisschem Healthcare Pvt Ltd

32. Global Pancreatic Cancer Drugs Market Competitive Benchmarking

33. Global Pancreatic Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pancreatic Cancer Drugs Market

35. Pancreatic Cancer Drugs Market Future Outlook and Potential Analysis

  • 35.1 Pancreatic Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Pancreatic Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Pancreatic Cancer Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제